2.87
0.03 (1.06%)
| Previous Close | 2.84 |
| Open | 2.81 |
| Volume | 1,697,016 |
| Avg. Volume (3M) | 3,499,416 |
| Market Cap | 782,921,664 |
| Price / Sales | 100.20 |
| Price / Book | 3.22 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Operating Margin (TTM) | -930.54% |
| Diluted EPS (TTM) | -0.340 |
| Quarterly Revenue Growth (YOY) | -32.50% |
| Total Debt/Equity (MRQ) | 111.93% |
| Current Ratio (MRQ) | 5.35 |
| Operating Cash Flow (TTM) | -83.45 M |
| Levered Free Cash Flow (TTM) | -52.28 M |
| Return on Assets (TTM) | -35.91% |
| Return on Equity (TTM) | -159.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Taysha Gene Therapies, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.75 |
|
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 12.11% |
| % Held by Institutions | 67.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Siren, L.L.C. | 30 Jun 2025 | 11,014,737 |
| Jefferies Financial Group Inc. | 30 Jun 2025 | 10,313,733 |
| Deerfield Management Company, L.P. | 30 Jun 2025 | 5,386,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 14.00 (Canaccord Genuity, 387.81%) | Buy |
| Median | 8.00 (178.75%) | |
| Low | 6.00 (JMP Securities, 109.06%) | Buy |
| Average | 9.00 (213.59%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 2.78 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 13 Aug 2025 | 14.00 (387.80%) | Buy | 3.03 |
| 03 Jun 2025 | 11.00 (283.28%) | Buy | 2.78 | |
| Wells Fargo | 13 Aug 2025 | 8.00 (178.75%) | Buy | 3.03 |
| Chardan Capital | 12 Aug 2025 | 10.00 (248.43%) | Buy | 2.91 |
| 29 May 2025 | 9.00 (213.59%) | Buy | 2.75 | |
| B of A Securities | 11 Jul 2025 | 8.00 (178.75%) | Buy | 2.64 |
| Needham | 01 Jul 2025 | 8.00 (178.75%) | Buy | 2.34 |
| 10 Jun 2025 | 8.00 (178.75%) | Buy | 2.61 | |
| JMP Securities | 29 May 2025 | 6.00 (109.06%) | Buy | 2.75 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |